Avidity Biosciences, Inc. (RNA) financial statements and ratios from SEC XBRL: revenue $18.75M (TTM), net margin -3650.4%, revenue growth -21.9% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (TTM) | $18.75M |
| Net Margin | -3650.4% |
| Revenue Growth (YoY) | -21.9% |
| EPS Growth (YoY) | 57.3% |
| FCF Growth (YoY) | 59.8% |
| Price / Book | 1.06 |
| Price / Sales | 4.14 |
| FCF Yield | -261.6% |
| Altman Z-Score | 0.24 (distress) |
| Sector P/E (Healthcare) | 21.7 |
RNA overview · RNA earnings · RNA KPIs · RNA investor relations · RNA ownership · RNA peers · RNA filings
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.